Google
×
AllNewsImagesBooks Maps Videos Shopping
Search tools

Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation | Bone Marrow Transplantation

Nature
In patients undergoing haematopoietic stem-cell transplantation (HSCT), the intestinal microbiota plays an important role in prognosis,...
7 months ago

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has...
3 weeks ago

How can Cytokine-induced killer cells overcome CAR-T cell limits

Frontiers
The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of...
8 months ago

(pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers

Business Wire
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers.
2 weeks ago

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carc

Business Wire
Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical...
3 weeks ago

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

PR Newswire
PRNewswire/ -- EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:...
44 months ago

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P182) | Bone Marrow Transplantation

Nature
The main objective of our study is to describe outcomes of allo-HCT in patients ≥60 years-old, and to investigate possible prognostic factors.
39 months ago

The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session

Nature
In this study, we analyzaed and compared the results of aplastic anemia patients who had undergone allogeneic stem cell transplantation either from matched...
63 months ago

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 – O169) | Bone Marrow Transplantation

Nature
QOL is poor in patients with grade III/IV aGVHD. Higher disease severity and inadequate response to steroids had the most negative effects.
39 months ago

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Business Wire
The application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator's choice of...
2 months ago